Alzheimer's: Drugs help manage symptoms

Alzheimer's still has no cure, but two types of drugs can help manage symptoms of the disease.

By Mayo Clinic Staff

Alzheimer's drugs might be one strategy to help slow or manage memory loss, thinking and reasoning problems, and day-to-day function. While Alzheimer's drugs don't cure the disease, they can improve quality of life and help prolong independence.

There are two types of medications approved to treat Alzheimer's: those that can temporarily ease some symptoms, and those that can slow the progression of the disease. Medications don't work for everyone, and they may lose effectiveness over time. They tend to be most effective for people with early to moderate Alzheimer's.

Research into more-effective Alzheimer's drugs is ongoing. If you can't take the approved medications or they don't work for you, ask your doctor if you might be eligible for a clinical trial.

Role of current Alzheimer's drugs

The Food and Drug Administration (FDA) has approved different types of drugs specifically to treat symptoms of Alzheimer's disease.

  • Cholinesterase inhibitors
  • Memantine

These drugs:

  • Are approved for specific Alzheimer's stages. These stages — mild, moderate and severe — are based on scores on tests that assess memory, awareness of time and place, and thinking and reasoning.

    Doctors might, however, prescribe Alzheimer's drugs for stages other than those for which the FDA has approved them. Alzheimer's stages aren't exact, individual responses to drugs vary and treatment options are limited.

    If your doctor prescribes medication as part of your Alzheimer's care plan, make sure you understand the drug's potential benefits and risks for your situation.

  • Are not approved for mild cognitive impairment (MCI). This condition, which involves subtle changes in memory and thinking, can be a transitional stage between normal age-related memory changes and Alzheimer's disease. Many people with MCI — but not all — eventually develop Alzheimer's or another dementia.

    Clinical trials testing whether Alzheimer's drugs might prevent progression of MCI to Alzheimer's have generally shown no lasting benefit.

Cholinesterase inhibitors

One way Alzheimer's disease harms the brain is by decreasing levels of a chemical messenger (acetylcholine) that's important for alertness, memory, thought and judgment. Cholinesterase (ko-lin-ES-tur-ays) inhibitors boost the amount of acetylcholine available to nerve cells by preventing its breakdown in the brain.

Cholinesterase inhibitors can't reverse Alzheimer's disease or stop the destruction of nerve cells. These medications eventually lose effectiveness because dwindling brain cells produce less acetylcholine as the disease progresses.

Common side effects can include nausea, vomiting and diarrhea. Starting treatment at a low dose and working up to a higher dose can help reduce side effects. Taking these medications with food also might help minimize side effects.

People with certain types of cardiac arrhythmias shouldn't take cholinesterase inhibitors.

Three cholinesterase inhibitors are commonly prescribed:

  • Donepezil (Aricept) is approved to treat all stages of the disease. It's taken once a day as a pill.
  • Galantamine (Razadyne) is approved to treat mild to moderate Alzheimer's. It's taken as a pill once a day or as an extended-release capsule twice a day.
  • Rivastigmine (Exelon) is approved for mild to moderate Alzheimer's disease. It's taken as a pill. A skin patch is available that can also be used to treat severe Alzheimer's disease.

Memantine for later stages

Memantine (Namenda) is approved by the FDA for treatment of moderate to severe Alzheimer's disease. It works by regulating the activity of glutamate, a messenger chemical widely involved in brain functions — including learning and memory. It's taken as a pill or syrup. Common side effects include dizziness, headache, confusion and agitation.

The FDA has also approved a combination of donepezil and memantine (Namzaric), which is taken as a capsule. Side effects include headache, dizziness, nausea and diarrhea.

When to discontinue Alzheimer's drugs

Because Alzheimer's is a progressive disease, your symptoms and care plan will change over time. If you're taking an Alzheimer's drug, ongoing review of your care plan will include working with your doctor to decide how long you should continue your medication.

Because the effects of Alzheimer's drugs are usually modest, it might be difficult to tell if the drugs are working. However, you can't know if your symptoms might be more severe without your medication.

Talk to your doctor before stopping an Alzheimer's drug, and let your doctor know if your condition worsens after you stop.

Working with your health care team can help you find the best strategies to manage your symptoms and prolong your independence.


This intravenous infusion therapy is the first drug of its kind to be approved for Alzheimer's disease. It is approved only for patients with mild cognitive impairment and mild dementia due to Alzheimer's disease.

The FDA approved aducanumab under an accelerated approval provision because it reduced brain beta-amyloid, a protein that is thought to be a key part of the Alzheimer disease pathway.

However, the benefits on daily functioning, thinking or memory aren't clear. Side effects can include:

  • Amyloid related imaging abnormalities-edema (ARIA-E), in which the brain swells (edema)
  • Amyloid related imaging abnormalities-hemosiderin deposition (ARIA-H), which includes small brain bleeds (microhemorrhage) and brain bleeding along the surface of the brain (superficial siderosis)

Repeated brain MRIs are needed to detect these changes.

Its current use is limited, because the Centers for Medicare & Medicaid Services (CMS) are working on plans to provide coverage for people with Medicare participating in CMS-approved randomized controlled trials.


Another Alzheimer's medicine, lecanemab, has shown promise for people with mild Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease. It could become available in 2023.

A phase 3 clinical trial found the medicine slowed cognitive decline in people with early Alzheimer's disease by 27%. Lecanemab works by preventing amyloid plaques in the brain from clumping. This was the largest study so far to look at whether clearing clumps of amyloid plaques from the brain can slow the disease.

Lecanemab is under review by the FDA. Another study is looking at how effective the medicine may be for people at risk of Alzheimer's disease, including people who have a close relative with the disease.

From Mayo Clinic to your inbox

Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID-19, plus expertise on managing health.

To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you. If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail.

Oct. 12, 2022 See more In-depth

See also

  1. Alzheimer's sleep problems
  2. Alzheimer's: New treatments
  3. Alzheimer's 101
  4. Alzheimer's and daily tasks
  5. Understanding the difference between dementia types
  6. Alzheimer's disease
  7. Alzheimer's disease: Can exercise prevent memory loss?
  8. Alzheimer's genes
  9. Alzheimer's nose spray: New Alzheimer's treatment?
  10. Alzheimer's prevention: Does it exist?
  11. Alzheimer's stages
  12. Alzheimer's and holidays
  13. Antidepressant withdrawal: Is there such a thing?
  14. Antidepressants and alcohol: What's the concern?
  15. Antidepressants and weight gain: What causes it?
  16. Antidepressants: Can they stop working?
  17. Antidepressants: Side effects
  18. Antidepressants: Selecting one that's right for you
  19. Antidepressants: Which cause the fewest sexual side effects?
  20. Anxiety disorders
  21. Atypical antidepressants
  22. Caregiver stress
  23. Clinical depression: What does that mean?
  24. Corticobasal degeneration (corticobasal syndrome)
  25. CT scan
  26. Depression and anxiety: Can I have both?
  27. Depression, anxiety and exercise
  28. What is depression? A Mayo Clinic expert explains.
  29. Depression: Diagnosis is key
  30. Depression in women: Understanding the gender gap
  31. Depression (major depressive disorder)
  32. Depression: Provide support, encouragement
  33. Depression: Supporting a family member or friend
  34. Diagnosing Alzheimer's
  35. Did the definition of Alzheimer's disease change?
  36. Intermittent fasting
  37. Male depression: Understanding the issues
  38. MAOIs and diet: Is it necessary to restrict tyramine?
  39. Marijuana and depression
  40. Mayo Clinic Minute: 3 tips to reduce your risk of Alzheimer's disease
  41. Mayo Clinic Minute: Alzheimer's disease risk and lifestyle
  42. Mayo Clinic Minute New definition of Alzheimer's changes
  43. Mayo Clinic Minute: Women and Alzheimer's Disease
  44. Mediterranean diet recipes
  45. Memory loss: When to seek help
  46. Monoamine oxidase inhibitors (MAOIs)
  47. MRI
  48. Natural remedies for depression: Are they effective?
  49. Nervous breakdown: What does it mean?
  50. New Alzheimers Research
  51. Pain and depression: Is there a link?
  52. Phantosmia: What causes olfactory hallucinations?
  53. Positron emission tomography scan
  54. Posterior cortical atrophy
  55. Seeing inside the heart with MRI
  56. Selective serotonin reuptake inhibitors (SSRIs)
  57. Serotonin and norepinephrine reuptake inhibitors (SNRIs)
  58. Brain anatomy
  59. Sundowning: Late-day confusion
  60. Treatment-resistant depression
  61. Tricyclic antidepressants and tetracyclic antidepressants
  62. Video: Alzheimer's drug shows early promise
  63. MRI
  64. Vitamin B-12 and depression
  65. Young-onset Alzheimer's